JPRN-UMIN000012193已完成未知
Efficacy of the anti-RANKL human antibody (Denosumab) versus Bisphosphonate for the treatment of osteoporosis in patients with primary biliary cirrhosis - Denosumab versus Bisphosphonate for osteoporosis in patients with PBC
Juntendo University School of Medicine0 个研究点目标入组 60 人开始时间: 2013年11月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Cancer patients with bone metastasis or expected bone metastasis 2) Hypocalcemia 3) Women who wish to be pregnant or are pregnant, or in lactation 4)Hypersensitivity to the denosumab 5)Cancer patients on cancer treatment or anti-hormonal therapy 6)Dental therapy during this trial 7)Long term use of bisphosphonate with the possibility of atypical fracture 8)severe skin infection
研究者
相似试验
已完成
不适用
Efficacy of a human anti-RANKL antibody (Denosumab) on prevention of steroid-induced osteoporosis in patients with autoimmune hepatitis (AIH)Biopsy-proven AIH patients who are planned or undergoing oral steroid therapy for more than 3 monthsJPRN-UMIN000013659Juntendo University School of Medicine80
已完成
不适用
Efficacy of anti-RANKL human antibody (Denosumab) on prevention of osteoporosis with primary biliary cirrhosisOsteoporosis in biopsy-proven PBC who was not pretreated with denosumab and/or bisphosphonate in recent 6 monthsJPRN-UMIN000012489Juntendo University School of Medicine20
进行中（未招募）
1 期
Effects of a treatment with Denosumab, applied together with either Nivolumab oder Pembrolizumab, in patients with skin cancer and bone metastasesEUCTR2016-001925-15-DEAlcedis GmbH20
已完成
4 期
Evaluation of immunological effects of the RANKL-inhibitor Denosumab when administered concurrently with PD1-blocking antibodies (Nivolumab, Pembrolizumab) in patients with metastatic malignant melanoma with bone involvementC43.9C79.5Malignant melanoma of skin, unspecifiedSecondary malignant neoplasm of bone and bone marrowDRKS00016064Alcedis GmbH17
已完成
不适用
Efficacy of anti-RANKL antibody on bone and mineral disorders in post-kidney transplant patients.Bone and mineral disorders after kidney transplantationJPRN-UMIN000013268Fujita Health University31